Additionally, glycolysis activation in pancreatic cancer can be reversed by an mTOR inhibitor (RAD001), and RAD001 in combination with gemcitabine can promote the chemotherapy sensitivity of PAAD cells (28). Here, MTOR is linked to pancreatic neoplasm.